Grifols SA ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $7.5B+2.4% YoYTTM through 31 Dec 2024
Net Income $162.4M+247.0% YoYTTM through 31 Dec 2024
Free Cash Flow $696.8MTTM through 31 Dec 2024
Margins
| Current | |
|---|---|
| Gross Margin | 38.0% |
| EBITDA Margin | 22.6% |
| Operating Margin | 16.5% |
| Net Margin | 2.2% |
Returns
52.9%ROE
20.4%ROA
0.9%ROIC
Balance Sheet Health
Debt / Equity1.27x
Current Ratio2.51x
Net Debt$8.8B
Cash & Equivalents$979.8M
Quality Metrics
Piotroski F-Score6 / 9
FCF Margin9.3%
Rule of 4016.0
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2024: $7.2B
Diluted EPSFY2024: $0.23
Dividend
$0.09Per share, FY20261.26%Yield-27.8%5-yr growth
Capital Allocation
Capex Intensity3.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biopharma | $6.5B | +8.4% | View detailsFocus on margin-enhanced EBITDA growth, self-sufficiency platforms in Egypt and Canada, and the launch of Fibrinogen. |
| Diagnostic | $1.1B | View detailsContinued progress on strategic milestones and expansion of transfusion safety technologies. | |
| Bio Supplies | $216M | View detailsLeverages massive donor center network of approximately 400 centers. |
Financials converted at 0.9610 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.